{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:45:52Z","timestamp":1787838352516,"version":"build-2784847793"},"reference-count":27,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T00:00:00Z","timestamp":1627516800000},"content-version":"unspecified","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2021,5,12]]},"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Secukinumab provided sustained efficacy, low radiographic progression and consistent safety over 52 weeks in patients with psoriatic arthritis (PsA) in the FUTURE 5 study. Here, we report 2-year (end-of-study) results from this study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults with active PsA were randomised 2:2:2:3 to receive subcutaneous secukinumab 300 mg load (300 mg), 150 mg load (150 mg), 150 mg no load or placebo at baseline; weeks 1, 2, 3 and 4; and every 4 weeks thereafter. Secukinumab could be escalated from 150 mg to 300 mg starting at week 52, if active signs of disease were observed based on physician\u2019s assessment. Assessments at week 104 (2 years) included clinical end points and radiographic damage (mean change in van der Heijde-modified total Sharp score (vdH-mTSS)). Safety analysis included all patients who received \u22651 dose of study medication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 996 patients randomised, 783 patients (78.6%) completed 2 years of treatment. Improvement in clinical end points was sustained through 2 years. The vdH-mTSS (mean change (SD)) was 0.10 (1.74; 300 mg), 0.52 (2.66; 150 mg) and 0.41 (2.20; 150 mg no load) at 2 years. The proportion of patients with no radiographic progression (change from baseline in vdH-mTSS \u22640.5) at 2 years was 89.5% (300 mg), 82.3% (150 mg) and 81.1% (150 mg no load).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Secukinumab with and without loading regimen provided sustained clinical efficacy and low radiographic progression through 2 years in patients with PsA. No new safety findings were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02404350\">NCT02404350<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2021-001600","type":"journal-article","created":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T10:33:00Z","timestamp":1627641180000},"page":"e001600","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":40,"title":["Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study"],"prefix":"10.1136","volume":"7","clinical-trial-number":[{"clinical-trial-number":"nct02404350","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J","family":"Mease","sequence":"first","affiliation":[{"name":"Rheumatology Research Division, Providence St. Joseph Health and University of Washington, Swedish Medical Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0577-6620","authenticated-orcid":false,"given":"Robert","family":"Landew\u00e9","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Amsterdam, Amsterdam, The Netherlands"},{"name":"Department of Rheumatology, Atrium Medical Centre, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Proton","family":"Rahman","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Memorial University of Newfoundland, St. John's, Newfoundland, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Tahir","sequence":"additional","affiliation":[{"name":"Rheumatology, Whipps Cross University Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Singhal","sequence":"additional","affiliation":[{"name":"Southwest Rheumatology, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Boettcher","sequence":"additional","affiliation":[{"name":"Rheumazentrum, Favoriten Hospital, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Navarra","sequence":"additional","affiliation":[{"name":"Section of Rheumatology, University of Santo Tomas Hospital, Manila, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Readie","sequence":"additional","affiliation":[{"name":"Rheumatology, Novartis Pharmaceuticals Corp, East Hanover, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shephard","family":"Mpofu","sequence":"additional","affiliation":[{"name":"Rheumatology, Novartis AG, Basel, Basel-Stadt, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eumorphia Maria","family":"Delicha","sequence":"additional","affiliation":[{"name":"Rheumatology, Novartis AG, Basel, Basel-Stadt, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luminita","family":"Pricop","sequence":"additional","affiliation":[{"name":"Rheumatology, Novartis Pharmaceuticals Corp, East Hanover, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-158X","authenticated-orcid":false,"given":"Desir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[{"name":"Rheumatology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,7,30]]},"reference":[{"key":"2025090313343809000_7.2.e001600.1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"2025090313343809000_7.2.e001600.2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032482"},{"key":"2025090313343809000_7.2.e001600.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-857X(05)70044-2"},{"key":"2025090313343809000_7.2.e001600.4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40744-016-0029-z","article-title":"Psoriatic arthritis and burden of disease: patient perspectives from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey","volume":"3","author":"Kavanaugh","year":"2016","journal-title":"Rheumatol Ther"},{"key":"2025090313343809000_7.2.e001600.5","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025090313343809000_7.2.e001600.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.056457"},{"key":"2025090313343809000_7.2.e001600.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"2025090313343809000_7.2.e001600.8","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.rdc.2015.07.007","article-title":"Imaging in psoriatic arthritis","volume":"41","author":"Poggenborg","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"2025090313343809000_7.2.e001600.9","first-page":"127","article-title":"Psoriatic arthritis (PSA)--an analysis of 220 patients","volume":"62","author":"Gladman","year":"1987","journal-title":"Q J Med"},{"key":"2025090313343809000_7.2.e001600.10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/30.4.245"},{"key":"2025090313343809000_7.2.e001600.11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg384"},{"key":"2025090313343809000_7.2.e001600.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5"},{"key":"2025090313343809000_7.2.e001600.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212687"},{"key":"2025090313343809000_7.2.e001600.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412679"},{"key":"2025090313343809000_7.2.e001600.15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13075-018-1551-x","article-title":"Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)","volume":"20","author":"Nash","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2025090313343809000_7.2.e001600.16","doi-asserted-by":"crossref","first-page":"700.1","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025090313343809000_7.2.e001600.17","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000723"},{"key":"2025090313343809000_7.2.e001600.18","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/rheumatology\/kez420","article-title":"Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5","volume":"59","author":"van der Heijde","year":"2020","journal-title":"Rheumatology"},{"key":"2025090313343809000_7.2.e001600.19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053"},{"key":"2025090313343809000_7.2.e001600.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.20775"},{"key":"2025090313343809000_7.2.e001600.21","first-page":"261","article-title":"How to read radiographs according to the Sharp\/van Der Heijde method","volume":"26","author":"van der Heijde","year":"1999","journal-title":"J Rheumatol"},{"key":"2025090313343809000_7.2.e001600.22","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1016\/S2665-9913(20)30036-9","article-title":"Long-Term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study","volume":"2","author":"McInnes","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2025090313343809000_7.2.e001600.23","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40744-019-0163-5","article-title":"Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study","volume":"6","author":"Kivitz","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2025090313343809000_7.2.e001600.24","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex301"},{"key":"2025090313343809000_7.2.e001600.25","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/acr.23111","article-title":"Secukinumab for long-term treatment of psoriatic arthritis: a two-year followup from a phase III, randomized, double-blind placebo-controlled study","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2025090313343809000_7.2.e001600.26","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/art.39685","article-title":"Brief report: Secukinumab provides significant and sustained inhibition of joint structural damage in a phase III study of active psoriatic arthritis","volume":"68","author":"van der Heijde","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025090313343809000_7.2.e001600.27","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1882-2"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2021-001600","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:34:43Z","timestamp":1756931683000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2021-001600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,7,30]]},"published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1136\/rmdopen-2021-001600"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2021-001600","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}